Immunotherapy developer Centauri Therapeutics has been awarded a £1 ($1.2) million grant by Pathways to Antimicrobial Clinical Efficacy (PACE), an initiative focused on early-stage antimicrobial drug and diagnostic discovery.   The funding will support the continued development of Centauri’s Alphamer technology, in this case targeting gram-negative bacteria including multi-drug resistant (MDR) bacterial strains.  Centauri’s lead anti-infective […]